Orion Pharma (DHA:ORIONPHARM) EBITDA: BDT433 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:ORIONPHARM Orion Pharma Ltd DHA:ORIONPHARM
72 GF Score
Price BDT30.10
GF Value BDT20.17
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Orion Pharma EBITDA?

Orion Pharma DHA:ORIONPHARM -2.27% 72 EBITDA is BDT433 Mil as of Mar. 2026. GuruFocus rates DHA:ORIONPHARM with a GF Score™ of 72/100 and a GF Value™ of BDT20.17 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Orion Pharma's EBITDA for the three months ended in Mar. 2026 was BDT140 Mil. Its EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was BDT433 Mil.

During the past 12 months, the average EBITDA Growth Rate of Orion Pharma was -64.50% per year. During the past 3 years, the average EBITDA Growth Rate was -26.70% per year. During the past 5 years, the average EBITDA Growth Rate was -20.30% per year. During the past 10 years, the average EBITDA Growth Rate was -7.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 12 years, the highest 3-Year average EBITDA Growth Rate of Orion Pharma was 14.60% per year. The lowest was -26.70% per year. And the median was -10.70% per year.

Orion Pharma's EBITDA per Share for the three months ended in Mar. 2026 was BDT0.60. Its EBITDA per share for the trailing twelve months (TTM) ended in Mar. 2026 was BDT1.85.

During the past 12 months, the average EBITDA per Share Growth Rate of Orion Pharma was -64.50% per year. During the past 3 years, the average EBITDA per Share Growth Rate was -26.70% per year. During the past 5 years, the average EBITDA per Share Growth Rate was -20.30% per year. During the past 10 years, the average EBITDA per Share Growth Rate was -7.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per share growth rate using EBITDA per Share data.

During the past 12 years, the highest 3-Year average EBITDA per Share Growth Rate of Orion Pharma was 14.60% per year. The lowest was -26.70% per year. And the median was -10.70% per year.

Orion Pharma  (DHA:ORIONPHARM) EBITDA Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals Operating Income. Operating Income is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses.. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies. Also Price-to-EBITDA is sometimes used in valuations.


Orion Pharma EBITDA Related Terms


Orion Pharma EBITDA Historical Data

* Premium members only.

The historical data trend for Orion Pharma's EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orion Pharma EBITDA Chart

Orion Pharma Annual Data
Trend Dec14 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,429.26 1,725.84 1,581.58 1,505.89 680.03

Orion Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 224.06 -0.35 146.71 146.02 140.23

DHA:ORIONPHARM vs CEG, VST, NRG: EBITDA Comparison

For the Utilities - Independent Power Producers subindustry, Orion Pharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orion Pharma EV-to-EBITDA vs Utilities - Independent Power Producers Industry

For the Utilities - Independent Power Producers industry and Utilities sector, Orion Pharma's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Orion Pharma's EV-to-EBITDA falls into.


DHA:ORIONPHARM
72GF Score
Orion Pharma Ltd DHA:ORIONPHARM
EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Orion Pharma's EBITDA for the fiscal year that ended in Jun. 2025 is calculated as

Orion Pharma's EBITDA was directly provided by GuruFocus' data source Morningstar. For the fiscal year ended in Jun. 2025, Orion Pharma's EBITDA was BDT680 Mil.

Orion Pharma's EBITDA for the quarter that ended in Mar. 2026 is calculated as

Orion Pharma's EBITDA was directly provided by GuruFocus' data source Morningstar. For the quarter ended in Mar. 2026, Orion Pharma's EBITDA was BDT140 Mil.

EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT433 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sometimes companies may have already deducted Depreciation and Amortization from Gross Profit. In this case Depreciation and Amortization needs to be added back when calculating EBITDA.

Frequently Asked Questions Learn more about EBITDA →
What does a EBITDA of BDT433 Mil mean?
Orion Pharma (DHA:ORIONPHARM) has a EBITDA of BDT433 Mil as of Mar. 2026. Ebitda is the difference between operating revenue and operating expenses not including depreciation and amortization. View historical data on Orion Pharma.
Is Orion Pharma's EBITDA too high?
Orion Pharma's current EBITDA is BDT433 Mil. Overall, Orion Pharma has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orion Pharma's EBITDA compare to CEG and VST?
Orion Pharma's EBITDA of BDT433 Mil can be compared against companies in the Utilities - Independent Power Producers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA for an Utilities - Independent Power Producers company?
A good EBITDA depends on the Utilities - Independent Power Producers industry context. However, EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA mean?
A high EBITDA can signal that a stock is expensive relative to its fundamentals. Ebitda is the difference between operating revenue and operating expenses not including depreciation and amortization. View historical data on Orion Pharma. Orion Pharma's current EBITDA is BDT433 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Pharma stock overvalued right now?
Based on GuruFocus' analysis, Orion Pharma (DHA:ORIONPHARM) is currently considered Significantly Overvalued. The stock's GF Value™ is BDT20.17, compared to a current price of BDT30.10 — trading 49.2% above its estimated fair value. The current EBITDA is BDT433 Mil. Orion Pharma's overall GF Score™ is 72/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA calculated?
EBITDA is calculated from a company's financial statements. For Orion Pharma (DHA:ORIONPHARM), the current EBITDA is BDT433 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Orion Pharma (DHA:ORIONPHARM) Overvalued in 2026?

Based on GuruFocus' analysis, Orion Pharma stock appears to be overvalued. The current stock price of BDT30.10 is trading 49.2% above its estimated GF Value™ of BDT20.17. GuruFocus considers Orion Pharma to be Significantly Overvalued.

Key valuation signals for DHA:ORIONPHARM:

  • EBITDA: BDT433 Mil
  • GF Value™: BDT20.17 vs. price of BDT30.10 (49.2% above fair value)
  • GF Score™: 72/100 with 8 warning signs

No single metric tells the full story. See the DHA:ORIONPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Orion Pharma Business Description

Address 153-154 Tejgaon Industrial Area, Orion House, Dhaka, BGD, 1208
Orion Pharma Ltd is a pharmaceutical company engaged in the creation and discovery, development, manufacturing, and marketing of pharmaceutical products, including vaccines and health-related consumer products. The company produces diversified dosage forms such as tablets, capsules, syrups, solutions, suspensions, powder for suspensions, creams, ointments, and injections under therapeutic categories including cardiovascular, antiulcerant, antiasthmatic, antihistamine, NSAIDs, antibiotic, antifungal, laxatives, anticancer, vitamins, and minerals. In addition, the company is involved in power generation activities and generates maximum revenue from pharmaceutical activities. The group principally carries out its business operations and markets its products in Bangladesh.
72GF Score

Get the complete analysis for DHA:ORIONPHARM

EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT30.10
Price
BDT20.17
GF Value